AcelRx Pharma Files $150M Mixed Shelf
AcelRx Pharma (ACRX) has filed $150,000,000 mixed shelf of:Common StockPreferred StockDebt SecuritiesWarrants
Strong Buy
or
AcelRx News & Analysis
-
-
AcelRx Pharma Receives Nasdaq Non-compliance Notice
On October 18, 2023, AcelRx Pharma (ACRX) received written notice (the “Notice”) from the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it is not in compliance with the...
-
AcelRx Pharma Receives IDE Approval for Niyad and Advances to a Single Registration Study
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically...
-
Alliance Global Partners initiates coverage of AcelRx at 'buy' with a price target of $4.2500
An analyst from Alliance Global Partners initiated coverage of AcelRx (NASDAQ: ACRX) at 'buy' with a price target of $4.2500. Prior to this rating, AcelRx had 1 buy ratings, 0 hold...
-
H.C. Wainwright maintains AcelRx at 'buy' with a price target of $5.0000
An analyst from H.C. Wainwright maintained AcelRx (NASDAQ: ACRX) at 'buy' with a price target of $5.0000 from a prior price target of $8.0000. Prior to this rating, AcelRx had 0 buy...
-
H.C. Wainwright upgrades AcelRx to 'buy' with a price target of $8.00
An analyst from H.C. Wainwright upgraded AcelRx (NASDAQ: ACRX) from 'neutral' to 'buy' with a price target of $8.00. Prior to this rating, AcelRx had 0 buy ratings, 1 hold ratings, and 0...
-
AcelRx Pharma Announces Offering by Selling Stockholders
AcelRx Pharma (ACRX) has just filed for offering of the following:This prospectus relates to the proposed resale from time to time by the selling stockholders of:up to 5,340,591 shares of...
-
AcelRx Pharma Announces 5.34M Share Private Placement at $1.36/sh
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use...
-
AcelRx earnings missed by $0.71, revenue fell short of estimates
Investing.com - AcelRx (NASDAQ: ACRX) reported fourth quarter EPS of $-0.7500, $0.71 worse than the analyst estimate of $-0.0400. Revenue for the quarter came in at $252K versus the...
-
AcelRx Pharma Announces Peer-Reviewed Publication On the Use of DSUVIA
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced the publication of a report arising from a series of rhinology procedures successfully performed using sufentanil sublingual...
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.12%
Investing.com – U.S. equities were higher at the close on Thursday, as gains in the Oil & Gas, Technology and Consumer Goods sectors propelled shares higher. At the close in NYSE, the Dow...
-
AcelRx Pharma Reports In-Line Q1 EPS
AcelRx Pharma (ACRX) reported Q1 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $442 thousand versus the consensus estimate of $550...
-
U.S. shares lower at close of trade; Dow Jones Industrial Average down 3.15%
Investing.com – U.S. equities were lower at the close on Wednesday, as losses in the Technology, Industrials and Oil & Gas sectors propelled shares lower. At the close in NYSE, the Dow...
-
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.14%
Investing.com – U.S. equities were lower at the close on Thursday, as losses in the Telecoms, Consumer Services and Oil & Gas sectors propelled shares lower. At the close in NYSE, the Dow...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
